TW221378B - - Google Patents

Info

Publication number
TW221378B
TW221378B TW081108170A TW81108170A TW221378B TW 221378 B TW221378 B TW 221378B TW 081108170 A TW081108170 A TW 081108170A TW 81108170 A TW81108170 A TW 81108170A TW 221378 B TW221378 B TW 221378B
Authority
TW
Taiwan
Prior art keywords
matter
compositions
preventing
amount
antibiotic
Prior art date
Application number
TW081108170A
Other languages
English (en)
Inventor
H Miller George
Y Kwon Heewon
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of TW221378B publication Critical patent/TW221378B/zh

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
TW081108170A 1991-10-16 1992-10-14 TW221378B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77786491A 1991-10-16 1991-10-16

Publications (1)

Publication Number Publication Date
TW221378B true TW221378B (zh) 1994-03-01

Family

ID=25111545

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081108170A TW221378B (zh) 1991-10-16 1992-10-14

Country Status (27)

Country Link
US (1) US5624914A (zh)
EP (2) EP0610295A1 (zh)
JP (1) JP2614407B2 (zh)
KR (1) KR100249584B1 (zh)
CN (1) CN1035923C (zh)
AT (1) ATE156019T1 (zh)
AU (1) AU678344B2 (zh)
CA (1) CA2121345C (zh)
DE (1) DE69221252T2 (zh)
DK (1) DK0538011T3 (zh)
ES (1) ES2104845T3 (zh)
FI (1) FI941723A0 (zh)
GR (1) GR3024800T3 (zh)
HK (1) HK1001085A1 (zh)
HR (1) HRP921069B1 (zh)
HU (1) HUT75157A (zh)
IL (1) IL103446A (zh)
MX (1) MX9205922A (zh)
NO (1) NO307326B1 (zh)
NZ (1) NZ244735A (zh)
PH (1) PH31675A (zh)
PL (1) PL170591B1 (zh)
SI (1) SI9200260A (zh)
TW (1) TW221378B (zh)
WO (1) WO1993007904A1 (zh)
YU (1) YU48722B (zh)
ZA (1) ZA927923B (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380172B1 (en) 1991-10-16 2002-04-30 Schering Corporation Monomeric lipophilic oligosaccharide antibiotic compositions
US5948688A (en) * 1991-10-16 1999-09-07 Schering Corporation Method of determining monomeric drug content
US5652226A (en) * 1995-12-22 1997-07-29 Schering Corporation Water soluble antibiotics
US5776912A (en) * 1996-12-20 1998-07-07 Schering Corporation Lipophilic oligosaccharide antibiotic compositions
US5763600A (en) * 1997-04-18 1998-06-09 Schering Corporation Oligosaccharide antibiotics and process for preparation thereof
ES2245805T3 (es) * 1997-10-03 2006-01-16 Galenica Pharmaceuticals, Inc. Polisacaridos que forman iminas, preparacion de los mismos y el uso de los mismos como adyuvantes de inmunoestimulantes.
US6162910A (en) * 1998-11-30 2000-12-19 Schering Corporation Process for preparing lipophilic oligosaccharide antibiotics
US6320044B1 (en) 1998-12-18 2001-11-20 Schering Corporation Process for recovering lipophilic oligosaccharide antibiotics
CO5231233A1 (es) * 1998-12-18 2002-12-27 Cherinf Corp Proceso para recuperar antibioticos oligosacaridos lipofilic lipofilicos
AU2003201A (en) * 1999-12-01 2001-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel use of lung surfactant
US6861513B2 (en) 2000-01-12 2005-03-01 Schering Corporation Everninomicin biosynthetic genes
CA2408008C (en) * 2000-05-02 2011-01-18 Theravance, Inc. Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
WO2002032459A2 (en) * 2000-10-17 2002-04-25 Massachusetts Institute Of Technology Method of increasing the efficacy of antibiotics by complexing with cyclodextrins
DE10109166A1 (de) * 2001-02-25 2002-09-12 Combinature Biopharm Ag Avilamycin-Derivate
RU2387665C2 (ru) * 2004-03-17 2010-04-27 Панакос Фармасьютикалз, Инк. Фармацевтические соли 3-о-(3', 3'-диметилсукцинил)бетулиновой кислоты
EP1987935A3 (en) * 2004-12-01 2008-11-19 Nitto Denko Corporation Foam Filling Member
US7799768B2 (en) * 2005-04-12 2010-09-21 Myrexis, Inc. Polymorphs of 3-O-(3′,3′-dimethylsuccinyl)betulinic acid di-N-methyl-D-glucamine
JP5503543B2 (ja) * 2007-09-14 2014-05-28 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物
JP2010095454A (ja) * 2008-10-14 2010-04-30 Cyclochem:Kk 抗菌組成物
EP2663338B1 (en) * 2011-01-14 2024-03-06 Emory University Glucose-based oligosaccharides comprising a positron-emitting radionuclide and their use for imaging
AU2016276774A1 (en) 2015-06-10 2018-01-18 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
CN106317143B (zh) * 2016-08-23 2020-10-30 河北圣雪大成制药有限责任公司 一种提取阿维拉霉素的方法
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR128F (zh) * 1962-04-02
US3915956A (en) * 1973-07-09 1975-10-28 Schering Corp Reduction products of everninomicins and methods for their manufacture
US3920629A (en) * 1973-09-19 1975-11-18 Schering Corp Desevernitrose everninomicins and method for their manufacture
US4006225A (en) * 1973-10-31 1977-02-01 Schering Corporation Method of using reduction products of everninomicins as antibacterial agents and pharmaceutical compositions useful therefor
US3998708A (en) * 1976-01-19 1976-12-21 Schering Corporation Electrochemical process for preparing hydroxylaminoeverninomicins
US4027016A (en) * 1976-01-19 1977-05-31 Schering Corporation Everninomicin antibacterial derivatives, electrochemical method for their manufacture, method for their use as antibacterial agents, and pharmaceutical compositions useful therefor
US4129720A (en) * 1977-02-14 1978-12-12 Schering Corporation Aminoeverninomicin and derivatives thereof
US4597968A (en) * 1982-08-06 1986-07-01 Schering Corporation Antibiotic 13-384 complex from Micromonospora carbonacea var africana
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4735903A (en) * 1984-06-21 1988-04-05 Schering Corporation Micromonospora carbonacea var africana
US4870060A (en) * 1985-03-15 1989-09-26 Janssen Pharmaceutica Derivatives of γ-cylodextrin
US4622314A (en) * 1985-10-15 1986-11-11 Schering Corporation Substituted oligosaccharide antibiotics
US4767748A (en) * 1985-10-15 1988-07-30 Schering Corporation Substituted oligosaccharide antibodies
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도

Also Published As

Publication number Publication date
ZA927923B (en) 1993-04-26
PL170591B1 (pl) 1997-01-31
JP2614407B2 (ja) 1997-05-28
HUT75157A (en) 1997-04-28
FI941723A (fi) 1994-04-14
CA2121345C (en) 1998-08-25
YU92192A (sr) 1996-01-09
HRP921069A2 (en) 1994-12-31
AU2780692A (en) 1993-05-21
CN1035923C (zh) 1997-09-24
EP0610295A1 (en) 1994-08-17
NZ244735A (en) 1995-12-21
CN1073359A (zh) 1993-06-23
NO941276L (no) 1994-04-08
DK0538011T3 (da) 1997-09-08
JPH06510546A (ja) 1994-11-24
YU48722B (sh) 1999-07-28
MX9205922A (es) 1994-08-31
SI9200260A (en) 1993-06-30
ATE156019T1 (de) 1997-08-15
DE69221252T2 (de) 1998-01-22
FI941723A0 (fi) 1994-04-14
WO1993007904A1 (en) 1993-04-29
KR100249584B1 (ko) 2000-04-01
IL103446A0 (en) 1993-03-15
US5624914A (en) 1997-04-29
EP0538011B1 (en) 1997-07-30
GR3024800T3 (en) 1998-01-30
NO941276D0 (no) 1994-04-08
PH31675A (en) 1999-01-18
HK1001085A1 (en) 1998-05-22
ES2104845T3 (es) 1997-10-16
HRP921069B1 (en) 1999-12-31
CA2121345A1 (en) 1993-04-29
DE69221252D1 (de) 1997-09-04
EP0538011A1 (en) 1993-04-21
AU678344B2 (en) 1997-05-29
HU9401104D0 (en) 1994-07-28
IL103446A (en) 1997-02-18
NO307326B1 (no) 2000-03-20

Similar Documents

Publication Publication Date Title
TW221378B (zh)
ZA928170B (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of alpha-D-neuraminic acid
GB9204761D0 (en) Compositions
HUT61989A (en) Process for producing 2-deoxy-2,3-didehydro-n-acetylneuraminic acid derivatives and analogs, as well as pharmaceutical compositions comprising same as active ingredient
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
HUT64013A (en) Process for producing hiv-inhibiting phenylacetamide derivatives and pharmaceutical compositions comprising such compounds as active ingredient
HUT61004A (en) Process for producing quinoxaline derivatives and pharmaceutical compositions comprising such compounds as active ingredient
IL102814A0 (en) Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them
IL101358A0 (en) Crystalline tiagabine hydrochloride monohydrate,its preparation and pharmaceutical compositions containing it
BG104436A (en) The administration of macrolides for the treatment of cancer and macular degeneration
EP0620004A4 (en) MEDICAL COMPOSITION.
UA42733C2 (uk) Похідні біснафталіміду та їх фармацевтично прийнятні кислотно-адитивні солі, фармацевтична композиція з цитотоксичною активністю, яка їх містить
GEP20032970B (en) Pharmaceutical Compositions of Tizoxanide and Nitazoxanide
DK0524696T3 (da) Orale præparater indeholdende dapiprazol
PL308580A1 (en) Solid pharmaceutical composition for oral administration and method of preparing same
AP9801235A0 (en) Erythromycin derivatives.
IL97648A0 (en) Stabilized 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide pharmaceutical compositions and methods for the preparation thereof
IE43125L (en) Aminoglycoside derivative
HUT61740A (en) Process for producing 2-piperidinyl-pyrimidine-4-carboxamide derivatives and pharmaceutical compositions comprising such compounds as active ingredient
IL57513A0 (en) 1,3-diaminopropan-2-ol derivatives,their preparation and pharmaceutical compositions containing them